New York Knicks guard Allonzo Trier has been one of the pleasant surprises from this year's rookie class. Team president Steve Mills is reportedly thrilled with his unexpected development thus far in his young NBA career, per Adam Zagoria of The New York Times Sports.

Trier was not selected in the 2018 NBA draft. Luckily though, the Knicks saw something in the 22-year old kid and signed him to a two-way deal in July.

As alluded to by Mills in his comments above, Trier had been involved in drug-related controversies in college. The former Arizona Wildcat was suspended indefinitely during his sophomore season for taking performance-enhancing drugs, which he took after getting involved in a car accident. He was also ruled ineligible in his junior year, for testing positive for allegedly the same substance, which, according to Arizona was a residue of what he took the year before.

Nonetheless, it seems like he has moved past that controversy and has found a home in New York. He made his NBA debut on October 17, scoring 15 points in 26 minutes against the Atlanta Hawks. The undrafted guard continued his consistent play and eventually earned a spot under head coach David Fizdale's rotation.

Trier has been on the shelf for seven games now due to a left hamstring strain. Despite the injury, the Knicks still rewarded Trier with an NBA contract, signing him to a 2-year $7-million deal. The second year of the deal is a team option.

In 27 games, Iso Zo is averaging 11.3 points, 3.1 rebounds, and 1.9 assists, and is shooting at an efficient 47 percent from the field and 39.1 percent from three.